Cruz Rivera, Samantha
Dickens, Andrew P. http://orcid.org/0000-0002-7591-8129
Aiyegbusi, Olalekan Lee http://orcid.org/0000-0001-9122-8251
Flint, Rebecca
Fleetcroft, Camilla
McPherson, Duncan
Collis, Philip
Calvert, Melanie J. http://orcid.org/0000-0002-1856-837X
Article History
First Online: 16 November 2021
Competing interests
: O.L.A. receives funding from the NIHR Birmingham Biomedical Research Centre, NIHR Applied Research Centre, West Midlands, at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd. and Janssen Pharmaceuticals, Inc. O.L.A. declares personal fees from Gilead Sciences Ltd., GlaxoSmithKline (GSK) and Merck outside the submitted work. M.J.C. is director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, director of the Centre for Patient Reported Outcomes Research and a National Institute for Health Research (NIHR) Senior Investigator. M.J.C. receives funding from the NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, UCB and GSK Pharma. M.J.C. has received personal fees from Astellas, Takeda, Merck, Daiichi Sankyo, Aparito Ltd., CIS Oncology, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. The other authors declare no competing interests. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care or the MHRA.